An earlier phase I single‐arm clinical trial in patients with recurrent or metastatic NPC showed overall response rates of patient groups treated with PD‐1 mAb alone and combined with GP of 34% and 91%, respectively.28 The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.